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The process of cell division, growth, differentiation and
death is a highly regulated process. Several class of trans
membrane receptors play a pivot role in this process, of
these, epidermal growth factor receptor (EGFR) a member
of Receptor Tyrosine Kinase (RTK) family are best known.
These comprises of four receptors Erb B1/HER 1, Erb B2 /
HER 2, Erb B3/ HER 3, and Erb B4 / HER 4. Of these HER
2 is the most favoured target.
Monoclonal Antibodies against EGFR
To target aberrant signalling through EGFR, monoclonal
antibodies were the first approach to be investigated. Lab-
oratory studies with murine monoclonal antibodies MAb
528 and MAB 225 demonstrated high affinity. IMC 225
[1], was the first antibody for clinical use that binds to
extra cellular domain of EGFR and blocks the binding of
activating ligands like EGFR and TGF-α. This inhibits
autophosphorylation of receptor, induces internalisation
of receptor and degradation of EGFR. This also causes p 27
inhibition and G1 cell cycle arrest.
The second antibody to be tested was ABX-EGF, which is
a human immunoglobulin G2 monoclonal antibody. The
mechanism of action is similar to that of IMC-225, how-
ever being completely human it does not produce immu-
nogenic response against antibody, which improves
efficacy and reduces premature termination of treatment
due to side effects. Its safety has been demonstrated in
phase I studies [2–5].
Small molecule inhibitors
An alternate strategy is to inhibit EGFR TK activity using
small molecules [6], like ZD 1839 (gefitinib, 'Iressa™';
Astra Zeneca) approved for use in lung cancer [7,1] and
several such other molecules like OSI-774, CI-1033 (PD
183805) and PKI-166 have been evaluated in phase I and
II trials while several others like EKB – 569, PD 168393,
GW 2016 and CGP 59326 are in pre-clinical trials. These
molecules act by inhibiting EGFR-TK thus inhibiting auto-
phosphorylation of EGFR [8,3].
The dream of inhibiting EGFR for its potential clinical use
has become a reality. The day is not for when anti EGFR
strategies will become another arrow in the quiver of anti-
cancer armamentarium of clinical oncologists.
References
1. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to
Epidermal Growth Factor Receptor Inhibitors in Non-Small
Cell Lung Cancer Cells: Limited Antiproliferative Effects and
Absence of Apoptosis Associated with Persistent Activity of
Extracellular Signal-regulated Kinase or Akt Kinase Path-
ways Clin Cancer Res 2003, 9:2316-2326.
2. Baselga J and Albanell J: Epithelial growth factor receptor inter-
acting agents Hematol Oncol Clin North Am 2002, 16:1041-1063.
3. Cohen RB: Epidermal growth factor receptor as a therapeutic
target in colorectal cancer Clin Colorectal Cancer 2003, 2:246-251.
4. Delbaldo C, Faivre S and Raymond E: [Epidermal growth factor
inhibitors] Rev Med Interne 2003, 24:372-383.
5. Grunwald V and Hidalgo M: Developing inhibitors of the epider-
mal growth factor receptor for cancer treatment J Natl Cancer
Inst 2003, 95:851-867.
6. Arteaga CL: ErbB-targeted therapeutic approaches in human
cancer Exp Cell Res 2003, 284:122-130.
7. Culy CR and Faulds D: Gefitinib Drugs 2002, 62:2237-2248.
8. Baselga J and Hammond LA: HER-targeted tyrosine-kinase inhib-
itors Oncology 2002, 63(Suppl 1):6-16.
Published: 01 July 2003
World Journal of Surgical Oncology 2003, 1:9
Received: 24 June 2003
Accepted: 01 July 2003
This article is available from: http://www.wjso.com/content/1/1/9
© 2003 Pandey and Chandramohan; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are 
permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.